Guest Blog by E. Adam Kallel PhD, Scientific Relations, CDD
My maternal grandfather died of tuberculosis. He contracted it while serving in the First World War. He returned from France to live a life of diminished quality, shortened by an early death. I can also remember, when I was a small child, in the 1970’s going for rides through Los Angeles’ Elysian Park area and passing what was then the Barlow Sanatorium. I asked my dad what a sanatorium was and was introduced at a young age to, what was still then, the isolating treatment of tuberculosis. The Barlow Sanatorium is now the Barlow Respiratory Hospital. Los Angeles, fortunately, no longer has the need for a facility dedicated to the treatment of TB.
My wife always tests positive with the Mantoux tuberculin skin test, the most common screening test for TB. She grew up in Kenya and was most likely sufficiently exposed, when she was young, to produce an antibody response without being infected. False positives in the Mantoux test are fairly common, leading to chest X-rays and sputum cultures being truly diagnostic. So I have had an unusually significant number of interactions with TB for a first world citizen.
TB has certainly been around since 9000 BC and probably became a human disease as a consequence of the domestication of cattle. Evidence has been found in Egyptian mummies from circa 3000 BC. TB has been a scourge of humanity for all this time. The death toll peaked in the 18th century when accounted for ~25% of all fatalities. The advent of the sanitarium movement followed by modern antibiotics with the discovery of streptomycin in 1946 made total eradication of TB seem like an obtainable goal. Then in the 1980’s the first drug resistant isolates were found, and we returned to the old days of an untreatable TB.
Since 1980 reported cases of tuberculosis have been rising steadily from 1,000,000/year to over 5,000,000/ year.
Approximately 1/3 of the world’s population is infected, and 3.7% of new and 20% reinfections involve some form of drug resistance. Total drug resistant TB has been found in Italy, India and Iran. It is unclear how extensive this strain is. Only 9% of TB cases are drug tested worldwide, making the extent of the problem largely unknown.
Fortunately the Bill and Melinda Gates Foundation (BMGF) is addressing this reemerging challenge head on. CDD was a partner in their efforts to unite researchers all over the world. CDD Vault is used by 250 researchers of TB in 58 laboratories across the world. CDD Vault allows the instantaneous sharing of data between these researchers and fosters collaboration. We won the 2011 Bio-IT World Editors’ Choice Award for Best Practices. I am proud to work for a company that takes the moral imperative to aid in solving this world problem. CDD is proud to be involved in this area as well.
Recently we released a free iOS app for iPhones and iPads which correlates anti-tuberculosis molecules with known targets allowing exploration of the pathways involved. CDD also hosts 13 public data sets which you can browse if the spirit moves you.
So on this World TB Day, I can pause and be thankful that we are helping bring researchers together to facilitate finding a cure for a disease that has crossed my path many times, in some odd, different ways.
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Translated with Google Translate